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Insulin-like growth factor (IGF) and insulin (INS) proteins regulate key cellular functions through a complex interacting multi-
component molecular network, known as the IGF/INS axis. We describe how dynamic and multilayer interactions give rise to the
multifunctional role of the IGF/INS axis. Furthermore, we summarise the importance of the regulatory IGF/INS network in cancer, and
discuss the possibilities and limitations of therapies targeting the IGF/INS axis with reference to ongoing clinical trials concerning the
blockage of IGF1R in several types of cancer.
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IGF/INS PROTEINS CONTROL AN INTERACTING
MULTIFUNCTIONAL REGULATORY NETWORK
Insulin-like growth factor (IGF) and insulin (INS) proteins
orchestrate a regulatory network of multiple components with
dynamic interactions, named herein the IGF/INS axis. Insulin-like
growth factor/INS proteins regulate crucial functions in tissue
homeostasis and malignant growth, including proliferation,
survival, tissue homeostasis, differentiation, energy supply, energy
consumption and cellular metabolism. The main sources of
circulating IGFs and INS are the liver and b-cells of the islets of
Langerhans of the pancreas, respectively. In addition, there are
local productions of IGFs and INS in many cells and tissues.
The IGF/INS axis is composed of the receptor ligands IGF1, IGF2
and INS, high-affinity (IGFBP) and low-affinity (IGFBP-rP)
IGF-binding proteins that exert modulatory functions, and the
receptors IGF1 receptor (IGF1R), IGF2 receptor (IGF2R), INS
receptor (INSR) and INSR-related receptor (IRR). Upon activation,
IGF/INSRs initiate a complex intracellular signaling network
across the major signaling pathways PI3K–AKT and RAS–RAF–
MAPK, and thus control a variety of cellular processes in normal
physiology and pathophysiology.
MULTIFUNCTIONAL EFFECTS IN PHYSIOLOGY AND
PATHOPHYSIOLOGY
To date, 15 molecular functions and 29 biological processes have
been linked to IGF1R, whereas 22 molecular functions and 47
biological processes have been linked to INSR in the gene ontology
database (http://www.geneontology.org; definitions: molecular
function, the elemental activities of a gene product at the
molecular level; biological process, operations or sets of molecular
events with a defined beginning and end, pertinent to the
functioning of integrated living units: cells, tissues, organs and
organisms. Query August 2010). This shows that the IGF/INS axis
is a multifunctional protein family and we can provide only an
outline of the best-characterised IGF/INS effects. The reader
should keep in mind the fact that the IGF/INS multifunctional
network will have additional functions, depending on the cell type
and the cellular context.
IGF/INS proteins are expressed ubiquitously, but in different
ratios and amounts, and exert auto-, para- and endocrine
biological effects in a variety of tissues and cells: (1) IGF/INS
growth factors act as growth hormones and regulate the growth of
human tissues and cells (Pollak, 2008). Severe growth retardations
were found in humans with defects in IGF/INS genes (Ohlsson
et al, 2009), whereas studies in knockout mice have confirmed the
pivotal role of the IGF/INS axis in normal growth (Ohlsson et al,
2009). Regulation of the life span has been associated with IGF
expression levels (Holzenberger et al, 2003). (2) The IGF/INS axis
is required to maintain tissue homeostasis (Sutherland et al, 2008)
and a differentiated phenotype in normal tissue (Belfiore et al,
2009). (3) The IGF/INS network influences the balance between
apoptosis and survival. IGFs are anti-apoptotic and pro-survival
factors—effects that are of major importance in the emergence and
progression of cancer (LeRoith and Roberts, 2003; Pollak, 2008).
(4) A further important function of the IGF/INS network is in
metabolism, where INS is a key regulator controlling cellular
glucose, amino-acid and fatty-acid uptake, as well as glycogen,
lipid and protein synthesis and a variety of other related metabolic
processes (Saltiel and Kahn, 2001). (5) The IGF/INS network is also
involved in angiogenesis, cell adhesion, migration and wound
healing (LeRoith and Roberts, 2003) and (6) (less known) exerts
multiple effects in the brain. It also influences mammalian
behavior and memory (Broughton and Partridge, 2009; Ohlsson
et al, 2009).
We do not entirely know how the IGF/INS axis mediates these
multiple functions, but experimental data have shown that
dynamic and multilayer IGF/INS interactions, and cross talks of
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as the epidermal growth factor receptor (EGFR) pathway, generate
variable IGF/INS signals in different cell types and tissues. The
different layers of diversity of signalling that give rise to the
multiple functions of the IGF/INS axis are schematically shown in
Figure 1 and explained in the following chapters. The variety of
cellular responses to the IGF/INS signal depend, on one hand, on
the availability of growth factors and the ratios of the receptors and
signalling molecules, and, on the other hand, on the cell and tissue
type and the tissue microenvironment.
IGF/INSRS – COMPLEXITY THROUGH HETERODIMER
FORMATION
IGF/INSRs include IGF1R, IGF2R, INSR, the latter existing in two
different isoforms, namely INSR-A and INSR-B, and IRR. IGF1R,
INSR and IRR are composed of an extracellular ligand-binding
domain and an intracellular protein kinase domain. Their
structural similarity permits the formation of heterodimer
receptors formed by subunits of different receptor proteins, such
as IGF1R/INSR and INSR/IRR heterodimers (Jui et al, 1996;
Pandini et al, 2002). Heterodimers are spontaneously formed when
the different receptors are expressed, and are the most abundant
receptor subtype in many tissues.
The receptors bind IGF and INS ligands with different affinities:
Ranking from high to low and very low affinity, IGF1R binds IGF1,
IGF2 and INS; IGF2R binds IGF2 and other ligands, such as
mannose-6-phosphate, IGF1 and INS; and INSR binds INS, IGF2
and IGF1 (Pandini et al, 2002; Ghosh et al, 2003; Belfiore et al,
2009). INSR-A has a higher IGF2 affinity than INSR-B (Belfiore
et al, 2009). IRR is an orphan receptor with unknown binding
ligand that participates in signal transduction as a heterodimer-
isation partner of the ligand-binding family members (Zhang and
Roth, 1992). Evidently, the subunit composition of receptors
determines their affinity for ligands. For instance, IGF1R/INSR-A
heterodimers possess a high affinity for IGF2 (Pandini et al, 2002;
Belfiore et al, 2009).
It is of note that IGF1R/EGFR heterodimers have also
been characterised (Morgillo et al, 2006), but their abundance
and ligand affinity remain unclear. A few reports describe
the occurrence of a soluble INSR that is secreted from cultured
human cells (Papa et al, 1993) and appears in human plasma
(Pezzino et al, 1992). This soluble INSR was shown to bind
INS (Papa et al, 1993); its IGF binding has not yet been
investigated.
Taken together, the classical view that IGFs bind and activate
IGF1R and INS activates INSR greatly simplifies the biological
situation in which IGF/INS-responsive receptors constitute a
complex interacting receptor network. Depending on the avail-
ability of IGF/INS ligands and the ratios of IGF/INS-responsive
receptors, IGFs can also activate INSR and, conversely, INS
activates IGF1R.
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Figure 1 The IGF/INS axis is a complex multilayer interacting molecular network with multiple effects.
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IGF1 and IGF2 are bound by six high-affinity binding proteins,
named IGFBP from IGFBP1 to IGFBP6, and several low-affinity
binding proteins, known as IGFBP-related proteins (IGFBP-rPs).
IGFBPs and IGFBP-rPs have different degrees of IGF affinity:
IGFBP1–IGFBP5 have higher affinities for IGF1, whereas IGFBP6
has a higher affinity for IGF2 (Firth and Baxter, 2002). Moreover,
IGFBPs and IGFBP-rPs have the ability to bind INS, but with a very
low affinity (Hwa et al, 1999).
IGF/IGFBP complexes exert two principal functions: first, they
stabilise IGFs and protect them from degradation, thus extending
their lifespan from a few minutes to several hours. Second, they
inhibit the binding of IGFs to their receptors. Therefore, only IGFs
that are released from IGFBPs by dissociation or protease-
mediated IGFBP cleavage can induce IGF signals (reviewed by
Hwa et al, 1999; Firth and Baxter, 2002).
In general, these IGF-related effects are similar and, in part,
redundant for all IGFBPs. However, different IGFBP affinities,
structures and post-translational modifications (Hwa et al, 1999), as
well as the presence of specific IGFBP proteases (Sadowski et al, 2003)
and IGFBP-binding extracellular matrix components (Nam et al,
2002), influence the effects of IGFBPs and permit fine-tuning of
IGF/IGFBP interactions in different tissues and tissue areas. IGFBP
binding to IGFs is usually inhibitory for receptor activation, but
under certain circumstances IGFBPs can promote IGF signalling and
may have pro-oncogenic effects. IGFBPs stabilise and slowly release
IGFs for receptor interactions, thereby preventing receptor down-
regulation by high IGF exposure. Thus, they promote a prolonged
and constant receptor activation (Firth and Baxter, 2002).
Beside their functions in IGF complexes, IGFBPs and IGFBP-rPs
exert effects that are independent of IGF binding or signalling and
specific for single IGFBPs and IGFBP-rPs. For instance, IGFBP-3
was found to act as an anti-cancer protein by inhibiting
proliferation, adhesion and motility by IGF-independent mechan-
isms (Firth and Baxter, 2002). IGFBP-rP1 (IGFBP7) was described
to have a central role in BRAF-mediated senescence and apoptosis
in melanoma cells (Wajapeyee et al, 2008). Taken together,
IGF/IGFBP complexes are tightly regulated and highly dynamic
extracellular complexes that modulate the IGF/INS signal by
influencing IGF/INS ratios, growth factor stabilities, receptor
binding and duration of receptor activation.
IGF/INSR DOWNSTREAM SIGNALLING PATHWAYS
IGF1R, INSR and IRR are tyrosine kinase receptors that initiate an
intracellular signal upon receptor activation. The signal transduc-
tion is mediated by both homo- and heterodimer receptors. Not
only in homodimers but also in heterodimers both parts of the
receptor can be activated upon ligand binding. Thus, IGF1R/INSR
heterodimers activate IGF1R and INSR signalling (Belfiore et al,
2009), and INSR/IRR heterodimers activate INSR, and also the
orphan IRR (Zhang and Roth, 1992).
IGF2R has no apparent intracellular signal and is believed to act
as a scavenger receptor for IGFs. The main function of IGF2R is
related to other pathways rather than IGF signalling: IGF2R is
required for the delivery of acid hydrolases from the Golgi network
to endosomes and lysosomes (Ghosh et al, 2003). The role of the
soluble INSR in the IGF/INS axis is yet to be investigated, but the
soluble INSR may also well function as a scavenger receptor,
thereby reducing the extracellular availability of INS.
IGF/INS signal transduction may be summarised as follows:
IGF/INS binding to IGF1R and INSR homo- and heterodimers
induces receptor clustering, autophosphorylation, and stimulation
of receptor tyrosine kinase activity, leading to the recruitment
and phosphorylation of IRS-1 and Shc, which activate (directly
or by association with Grb-2/SOS) the two signalling pathways
PI3K–AKT and RAS–RAF–MAPK. These pathways, in turn,
initiate a variety of intracellular signalling cascades that have
multiple effects on gene regulation and protein expression,
activation and translocation (LeRoith and Roberts, 2003). How-
ever, the IGF/INS signal is more complex than this simplified view
suggests: a variety of other substrates for IGF1R and INSR, such as
other IRSs, Gab1, Cbl, APS, SHP2, Fyn and Csk, have been
described (Belfiore et al, 2009). Availability, location and ratios of
these receptor substrates significantly influence cellular responses
upon IGF1R and INSR activation. Some of the main signalling
molecules, such as PI3K, appear in different isoforms that have
different activation and effector properties (Saltiel and Kahn,
2001). Several cross-talks of the IGF/INS signalling to other
pathways have been reported, which are mediated by interactions
of IGF1R and INSR with major signalling molecules of other
molecular pathways, such as SOCS interactions influencing the
JAK–STAT pathway (Dey et al, 1998), or interactions with other
receptors, such as IGF1R/EGFR heterodimers (Morgillo et al,
2006). Thus, IGFs and INS activate, by means of IGF1R and INSR, a
highly complex intracellular signaling network (Figure 2).
IGF1R and INSR have been reported to act through the same
pathways. However, subtle differences in the recruitment of docking
proteins and intracellular mediators cause a fine-tuned signalling
outcome that permits selective IGF1R or INSR signal transduction
(Pandini et al, 2002). These differences arise not only by different
substrate specificities for IGF1R and INSR, which probably do exist,
but are also mediated by different binding velocities, reaction times,
activities, expression levels and sub-cellular locations of signalling
molecules (Sasaoka et al, 1996; Biedi et al, 2003).
In summary, IGF/INS ligand binding leads to the activation of
IGF1R, INSR and IRR, which activate a complex signalling network
across the two major signalling pathways PI3K–AKT and RAS–
RAF–MAPK. With regard to the close and reciprocal interactions
of INS and IGF signalling in the IGF/INS network, the activation of
a single pathway (such as IGF signalling) with no activation of the
other pathway (such as INS signalling) appears to be unlikely.
However, fine-tuning of ligand availability, receptor ratios,
signalling molecule expression and localisation alter the signal,
thus allowing predominant activation of IGF/IGF1R or INS/INSR
signals in different cells and tissues.
THE IGF/INS AXIS AND CANCER
Evasion from apoptosis and a limitless replicative potential are two
hallmarks of cancer (Hanahan and Weinberg, 2000). Thus, growth
and survival pathways have emerged as appealing targets for
cancer therapy. As the IGF axis is a central regulator of growth and
survival, therapeutic strategies focusing on the blockage of IGF1R
and IGF signalling are currently being investigated for several
types of cancer in a large number of clinical trials. In the following
we will discuss the rationale underlying these trials, their power
and their limitations in respect of the IGF/INS network.
Cumulative evidence has been obtained concerning the role of
the IGF/INS network in the emergence and progression of cancer.
Genetic studies showed that the risk of cancer is influenced by
IGF/INS gene variants, and cancer-associated somatic copy
number variations are found in IGF/INS gene regions. Recent
examples are an IGF1 polymorphism associated with non-small-
cell lung cancer (Zhang et al, 2010), an IGF2R polymorphism
influencing the risk of oesophageal and gastric cancer (Hoyo et al,
2009), and the detection of a cancer-associated somatic copy
number amplification in the IGF1R gene region in a pooled
analysis of 26 cancer types, each represented by more than
20 specimens (Beroukhim et al, 2010). Epidemiological studies also
revealed that high IGF1 serum concentrations are associated with
prostate, colorectal and breast cancer (Renehan et al, 2004).
Epigenetic, expression and protein analyses have demonstrated
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tissues. Increased expression of IGF2 caused by loss of genomic
IGF2 imprinting (genomic imprinting: only one allele of the gene is
active, depending on the parental origin) was registered for
cervical cancer, choriocarcinoma, colorectal cancer, hepatoblasto-
ma, lung cancer, rhabdomyosarcoma, pediatric testicular cancer
and Wilms’ tumours (Ross et al, 1999; Chao and D’Amore, 2008).
IGF1R was found to be essential for oncogenic transformation in
certain cellular systems. Mouse fibroblasts lacking IGF1R cannot
be transformed by known oncogenes, such as SV40 T antigen,
papillomavirus E5 and overexpression of Ras (Sell et al, 1993).
Overexpression of a constitutively activated IGF1R was shown to
be sufficient to cause mammary epithelial cell transformation in
mouse models (Jones et al, 2007; Kim et al, 2007). In prostate
epithelial cells, however, re-expression of the IGF1R inhibited
the malignant phenotype of SV40 T antigen immortalised
human prostate epithelial cells (Plymate et al, 1997). Epithelial-
specific deletion of IGF1R accelerated the emergence of aggres-
sive prostate cancer when p53 activity was compromised
(Sutherland et al, 2008). These observations underscore the
importance of the IGF axis in carcinogenesis and tumour
progression and, on the other hand, show again that IGF/INS
effects are variable in different cell and tissue types, including
cancer.
IGF1R AS A TARGET FOR CANCER THERAPY
In current clinical trials, the main IGF/INS target for cancer
therapy is IGF1R. Other IGF/INS targets are approached indirectly:
IGFs are addressed by the use of somatostatin analogues, which
suppress their production, and IGF/INSRs through blockage of
receptor downstream molecules, using PI3K and AKT inhibitors
among other substances. More than 70 clinical trials investigating
the blockage of IGF1R are under way. Different anti-IGF1R
antibodies, as well as small-molecule IGF1R or IGF1R tyrosine
kinase inhibitors, are being investigated as stand-alone therapies
or in combination with conventional treatments for many cancers,
including breast cancer, colorectal cancer, leukaemia (ALL, CML),
non-small-cell lung cancer, ovarian cancer, pancreatic cancer,
prostate cancer and sarcoma (recently discussed and summarised
in Gualberto and Pollak, 2009). Most anti-IGF1R antibodies are
reported to be monospecific for IGF1R, whereas several small-
molecule inhibitors also inhibit IGF1R/INSR heterodimers and
INSR. Preliminary outcomes have suggested that the treatment is
well tolerated, although effects on metabolism, such as elevated
levels of circulating IGF1, INS and glucose levels, have been
reported. In some cases, anti-diabetic treatment was required to
control blood glucose levels (Gualberto and Pollak, 2009). The
efficacy of the treatment has not been fully explored thus far, but
encouraging data have been registered in a phase-II study
concerning the use of an anti-IGF1R antibody in non-small-cell
lung cancer. Promising results of anti-IGF1R therapy have also
been reported on patients with sarcomas in phase-I studies
(Gualberto and Pollak, 2009). These early studies justify the
investigation of IGF1R as a target for cancer therapy. However, a
phase-III study with an anti-IGF1R antibody combined with
erlotinib in advanced non-small-cell lung cancer was terminated
recently for safety reasons and lack of efficiency (ClinicalTrials.gov
Identifier: NCT00673049).
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Figure 2 IGF/INS ligand binding, to one or both receptor monomers, leads to the activation of IGF1R, INSR and IRR, which activate a complex signalling
network across the two major signalling pathways PI3K–AKT and RAS–RAF–MAPK (shown here in parts (for detailed signalling networks see Kyoto
Encyclopedia of Genes and Genomes pathway database (http://www.genome.jp/keg) and GeneGO pathway analysis database (http://www.genego.com)).
The IGF/INS axis regulates multiple functions in normal physiology and pathophysiology. IGF1R and INSR have been reported to act by means of the same
pathways. The signal is influenced by different binding velocities, reaction times, activities, expression levels and sub-cellular locations of signalling molecules.
Selective substrate specificities for IGF1R and INSR probably also exist.
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cancer therapy. Clinical trials targeting IGF1R must be designed
and controlled with care. Several limitations arise from the
complexity and multiple functions of the IGF/INS axis: (a) The
IGF/INS axis is a molecular network that exerts essential functions
in normal tissues (e.g. control of growth processes, tissue
homeostasis, differentiation and metabolism). Interfering with
the IGF/INS network may, therefore, cause severe side effects in
some tissues and cells. (b) A single anti-IGF1R therapy may be
inefficient. Resistance to anti-IGF1R therapy can occur because
of signal transduction by IGF/INS heterodimer receptors and
redundant effects with INSR. It was recently shown in a mouse
model for pancreatic neuroendocrine cancer that resistance to
anti-IGF1R therapy was overcome by disruption of the INSR gene
(Ulanet et al, 2010). Furthermore, mutations in major IGF1R
signalling molecules, such as the tumor suppressor PTEN affecting
the PI3K–AKT pathway (Zhao et al, 2004), and cross-talks with
other molecular pathways, such as EGFR (Morgillo et al, 2006;
Huang et al, 2009), can cause anti-IGF1R therapy resistance. (c) A
combined therapy targeted against IGF1R and INSR may be more
efficient, but will also affect glucose metabolism and provoke
diabetic symptoms. A combined therapy targeting IGF1R and
EGFR was shown to successfully inhibit tumour cells, which were
resistant to IGF1R blockage by overexpressing the EGFR pathway
(Huang et al, 2009). (d) Although IGF1R was reported to be
overexpressed in a variety of cancers, in some tumours the IGF
signal exerts a protective effect against tumour formation (Lewis
et al, 2009) and inhibits the emergence of an aggressive tumour
phenotype (Sutherland et al, 2008).
Taken together, the data reported thus far suggest that IGF1R is
an interesting target in cancer. However, several limitations arise
from the complexity and multifunctional role of the IGF/INS axis.
To overcome these limitations, a combined therapy focused on
IGF1R and other targets, such as EGFR, is a promising treatment
strategy for some types of cancer, but the patients must be selected
with great care to avoid severe side effects.
FUTURE DIRECTIONS
Reports from clinical trials give reason for optimism regarding the
use of IGF1R inhibitors in cancer patients. At the same time,
however, in some trials severe side effects and resistance to anti-
IGF1R treatment were observed. To control, predict and – in best
case – avoid side effects, we need a better understanding of the
function of the IGF/INS pathway in normal physiology, including
implications of the IGF/INS axis in normal growth, development,
differentiation and cellular metabolism. Furthermore, we need new
molecular markers to identify patients profiting of an anti-IGF1R
therapy. The clinical success of nearly all tyrosine kinase inhibitors
is predicted by appropriate tumour characterisation, such as
the presence of mutations or receptor overexpression. An elegant
approach to how such a characterisation could be achieved
was described by de Bono and coworkers. They confirmed
the expression of IGF1R by analysing circulating tumour cells
(de Bono et al, 2007). Such an analysis – extended to additional
molecular markers similar to IGF1R/EGFR expression levels and
receptor mutations, as well as alterations of key signalling
molecules, such as PTEN, p53 or k-ras – may help to achieve
individual tumour characterisation to increase response rates to
treatment, reduce side effects and avoid therapy resistance.
CONCLUSION
In the IGF/INS axis, IGF and INS proteins functionally cross-talk
with each other and form a dynamic mutually interacting
multilayer molecular network. This regulatory network exerts
multiple functions in normal physiology, but is also implicated in
the emergence and progression of cancer. Clinical trials with drugs
blocking IGF1R are in progress; their preliminary results have
been promising. However, the complexity, multiple functions, and
interactions of the IGF/INS axis are limiting factors, which may
cause side effects, as well as therapy resistance and pose a
challenge for accurate patient selection.
Extensive research in the last few decades has provided
important insights into the functions of the IGF/INS axis. Future
work should be aimed at a better understanding of the axis
as a whole, its role in normal physiology and pathophysiology, and
the implications of the manipulation of different components – for
example, with the help of systems biology approaches – to
establish mechanism-based use of inhibitors for the treatment of
cancer and other diseases.
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